University of California San Francisco

Wenhan Chang, PhD

Wenhan Chang, PhD
Wenhan Chang, PhD

Professor, Medicine
School of Medicine

Address

513 Parnassus Avenue HSW, #840
San Francisco, CA 94143
United States

Email: [email protected]

ORCID: 0000-0001-6583-7176

Education

Institution Degree Dept or School End Date
State University of New York PhD Physiology/Electrophysiology
University of California San Francisco Post-doc Endocrinology

Grants and Funding

  • BLRD Research Career Scientist Award Application | NIH | 2019-10-01 - 2029-09-30 | Role: Principal Investigator
  • UCSF Core Center for Musculoskeletal Biology in Medicine | NIH NIAMS | 2019-10-01 - 2029-09-30 | Role: Director of Skeletal Biology and Biomechanics Core
  • Vitamin D and beta-amyloid signaling in hyperparathyroidism | NIH | 2023-04-15 - 2028-03-31 | Role: Co-Principal Investigator
  • Vitamin D and beta-amyloid signaling in hyperparathyroidism | NIH/NIA | 2023-04-01 - 2028-03-31 | Role: Co-Principal Investigator
  • FRACTURE CURB: Combined long-acting PTH and calcimimetics actions on skeletal anabolism | VA BLR&D | 2021-10-01 - 2026-09-30 | Role: Principal Investigator
  • The role of Tau in mediating the effects of abeta(1-42) on the parathyroid gland in primary hyperparathyroidism | NIH | 2023-04-15 - 2026-03-31 | Role: Co-Principal Investigator
  • BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism | NIH | 2021-10-01 - 2025-09-30 | Role: Principal Investigator
  • Regulation of Parathyroid Functions By G-Protein Coupled Receptors | NIH | 2019-09-12 - 2024-08-31 | Role: Principal Investigator
  • Regulation of PTH secretion by TRPC1 | NIH | 2019-04-01 - 2024-03-31 | Role: Co-Principal Investigator
  • Regulation of parathyroid function by the amyloid precursor protein | NIH | 2021-05-01 - 2024-01-31 | Role: Co-Principal Investigator
  • ShEEP Request for NanoString GeoMx Digital Spatial Profiling System | NIH | 2023-03-01 - 2023-09-30 | Role: Principal Investigator
  • ShEEP Request for NanoString GeoMx Digital Spatial Profiling System | VA BLR&D | 2022-10-01 - 2023-09-30 | Role: Principal Investigator
  • A novel treatment for bone fracture repair | NIH | 2017-10-01 - 2021-09-30 | Role: Principal Investigator
  • The 4th Symposium on The Extracellular Calcium-Sensing Receptor | NIH | 2020-03-01 - 2021-02-28 | Role: Principal Investigator
  • ShEEP Equipment Request for GeoMx? Digital Spatial Profiler System | NIH | 2019-09-01 - 2020-09-30 | Role: Principal Investigator
  • Combined PTH and Calcimimetic Therapy and Its Mechanisms for Osteoanabolism | NIH | 2015-02-11 - 2020-06-30 | Role: Principal Investigator
  • UCSF Core Center for Musculoskeletal Biology and Medicine | NIH | 2014-07-01 - 2020-03-31 | Role: Co-director of Skeletal Biology Core
  • ShEEP Equipment Request for nCounter Max Analysis System | NIH | 2019-01-01 - 2019-09-30 | Role: Principal Investigator
  • ShEEP Request for Atomic Force Microscope (BRUKER INNOVA2-SYS) | NIH | 2018-01-01 - 2018-09-30 | Role: Principal Investigator
  • The Role of CaSR and GABA-B-R in Neuronal Responses to Ischemic Brain Injury | NIH | 2013-04-01 - 2017-03-31 | Role: Principal Investigator
  • ShEEP Request for SCANCO Medical VivaCT 80 preclinical micro-computed tomography (pCT) system | NIH | 2016-05-01 - 2016-09-30 | Role: Principal Investigator
  • CALCIUM-SENSING RECEPTORS AND GROWTH PLATE DEVELOPMENT | NIH | 2002-02-15 - 2014-03-31 | Role: Principal Investigator
  • INTERACTIONS BETWEEN GABA B AND CA2+-SENSING RECEPTORS | NIH | 2007-03-06 - 2010-02-28 | Role: Principal Investigator
  • Resolution of Stage-Specific Growth Plate Chondrocytes | NIH | 2003-09-25 - 2006-06-30 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Amyloid-β as a target to suppress tonic PTH hypersecretion in hyperparathyroidism due to vitamin D deficiency.
    Tu CL, Cheng Z, Szeto N, Savransky S, Glinin T, Herberger A, Shoback DM, Sosa JA, Vilardaga JP, Koh J, Chang W| | PubMed
  2. The emerging role of integrin signaling in pulmonary vascular disease.
    Bai AS, Sørensen GL, Sundaram AB, Chang W, Tuder RM, Graham BB, Lee MH| | PubMed
  3. Deletion of cardiac fibroblast growth factor-23 beneficially impacts myocardial energy metabolism in left ventricular hypertrophy.
    Latic N, Lari A, Sun N, Zupcic A, Oubounyt M, Falivene J, Buck A, Hofer M, Chang W, Kuebler WM, Baumbach J, Walch AK, Grabner A, Erben RG| | PubMed
  4. Transcriptional and neuroprotective effects of hexokinase-2 inhibitors administered after stroke.
    Won SJ, Uruk G, Mai N, Tu CL, Ogut D, Asatryan S, Mocanu E, Shon R, Kim K, Awakoaiye K, Arkelius K, Chang W, Singhal NS, Swanson RA| | PubMed
  5. Hypertension promotes bone loss and fragility by favoring bone resorption in mouse models.
    Hennen EM, Uppuganti S, de la Visitación N, Chen W, Krishnan J, Vecchi LA, Patrick DM, Siedlinski M, Lemoli M, Delgado R, de Caestecker MP, Chang W, Guzik TJ, Johnson RW, Harrison DG, Nyman JS| | PubMed
  6. β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism.
    Tu CL, Cheng Z, Szeto N, Savransky S, Glinin T, Shoback DM, Sosa JA, Vilardaga JP, Koh J, Chang W| | PubMed
  7. Extracellular Ca2+-Sensing Receptor (CaSR) Regulates Hypothalamic Function to Control Energy and Skeletal Metabolism in Mice.
    Park-Sigal J, Norton M, Tu CL, Cheng Z, Fadahunsi N, Lee H, Kim S, Li A, Grinberg LT, Bewick GA, Murphy KG, Chang W| | PubMed
  8. Targeted Deletion of Fibroblast Growth Factor 23 Rescues Metabolic Dysregulation of Diet-induced Obesity in Female Mice.
    Park MY, Tu CL, Perie L, Verma N, Serdan TDA, Shamsi F, Shapses S, Heffron S, Gamallo-Lana B, Mar AC, Alemán JO, Mueller E, Chang W, Sitara D| | PubMed
  9. Large library docking identifies positive allosteric modulators of the calcium-sensing receptor.
    Liu F, Wu CG, Tu CL, Glenn I, Meyerowitz J, Kaplan AL, Lyu J, Cheng Z, Tarkhanova OO, Moroz YS, Irwin JJ, Chang W, Shoichet BK, Skiniotis G| | PubMed
  10. The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).
    Yee CS, Meliadis C, Kaya S, Chang W, Alliston T| | PubMed